Incretin Atlas › Molecules › EloraTZP
EloraTZP
GIP/GLP-1 + amylin · s.c. · Eli Lilly
Summary
- Also known as
- eloralintide + tirzepatide, Eli Lilly
- Mechanism
- GIP/GLP-1 + amylin
- Route
- s.c.
- Company
- Eli Lilly
- Highest development stage
- phase 3
- Status (as of data cut)
- Phase 2b in obesity with T2D positive (Sep 2026: up to −23.3 % vs −14.8 % with tirzepatide 15 mg); phase 3 AMPLIFY-1 and AMPLIFY-2 registered (100 weeks, start Q4 2026) verify
- Next milestone
- AMPLIFY phase 3 start
Sources for the status
- Eli Lilly and Company. A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity Without Type 2 Diabetes (AMPLIFY-1). ClinicalTrials.gov identifier NCT07881432. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07881432
- Eli Lilly and Company. A Phase 3 Study to Investigate the Efficacy and Safety of LY900043 in Adult Participants With Obesity or Overweight and Type 2 Diabetes (AMPLIFY-2). ClinicalTrials.gov identifier NCT07881458. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT07881458
- Eli Lilly and Company. EloraTZP (eloralintide + tirzepatide) phase 2 results in adults with obesity and type 2 diabetes [press release]. 2026 Sep 30. Available from: https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html
Trial arms: weight, HbA1c and tolerability
| Trial | Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EloraTZP phase 2b (obesity + T2D) | EloraTZP 3/5 mg | t2d | 48 | — | −13.2 % vs −3.0 % Δ −10.2 pp | — | −2.2 vs −0.3 | — | — | — | — | — | — | press release |
| EloraTZP phase 2b (obesity + T2D) | EloraTZP 6/5 mg | t2d | 48 | — | −19.4 % vs −3.0 % Δ −16.4 pp | — | −2.7 vs −0.3 | — | — | — | — | — | — | press release |
| EloraTZP phase 2b (obesity + T2D) | EloraTZP 6/10 mg | t2d | 48 | — | −19.9 % vs −3.0 % Δ −16.9 pp | — | −2.6 vs −0.3 | — | — | — | — | — | — | press release |
| EloraTZP phase 2b (obesity + T2D) | EloraTZP 9/15 mg | t2d | 48 | — | −23.3 % vs −3.0 % Δ −20.3 pp | — | −2.9 vs −0.3 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- EloraTZP 3/5 mg: eloralintide 3 mg + tirzepatide 5 mg (separate injections)
- EloraTZP 6/5 mg: eloralintide 6 mg + tirzepatide 5 mg (separate injections)
- EloraTZP 6/10 mg: eloralintide 6 mg + tirzepatide 10 mg (separate injections)
- EloraTZP 9/15 mg: eloralintide 9 mg + tirzepatide 15 mg (separate injections)
Verbatim quotes from the source (4)
- EloraTZP 3/5 mg · weight_eff · press release table
Elora 3 mg + TZP 5 mg -13.2
- EloraTZP 6/5 mg · weight_eff · press release table
Elora 6 mg + TZP 5 mg -19.4
- EloraTZP 6/10 mg · weight_eff · press release table
Elora 6 mg + TZP 10 mg -19.9
- EloraTZP 9/15 mg · weight_eff · press release table
Elora 9 mg + TZP 15 mg -23.3
Registered trials (2)
From ClinicalTrials.gov and the atlas registry sweep; phase 3 and outcome trials first.
| Trial | Indication | Phase | Status | Start → primary completion | n | Result | Registry |
|---|---|---|---|---|---|---|---|
| AMPLIFY-1 A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Obesity | Phase 3 | not yet recruiting | 2026-12 → 2029-10 | 2115 | not yet recruiting | NCT07881432 |
| AMPLIFY-2 A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Obesity | Phase 3 | recruiting | 2026-10 → 2029-10 | 1000 | recruiting | NCT07881458 |
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: EloraTZP. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/eloratzp/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.